Press Releases Valneva

Equities

VLA

FR0004056851

Market Closed - Euronext Paris Other stock markets 11:35:14 2024-04-26 am EDT			5-day change	1st Jan Change
3.444 ^EUR	-0.06%		-5.95%	-27.03%

Apr. 11	Valneva: Deep Track Biotechnology Master holds less than 5% of the capital	CF
Mar. 26	Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valneva : Document AMF CP. 2024E960493	Apr. 16	PU
World Vaccine Congress Washington: Antibody persistence of a single-dose live-attenuated chikungunya virus vaccine in adults	Apr. 04	PU
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	Mar. 26	AQ
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate	Mar. 26	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	Mar. 25	GL
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F	Mar. 25	AQ
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	Mar. 21	AQ
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.	Mar. 21	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	Mar. 20	GL
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook	Mar. 20	AQ
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed	Mar. 18	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	Mar. 04	GL
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences	Mar. 04	AQ
U.S. CDC Advisory Committee Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ	Mar. 01	AQ
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®	Feb. 29	GL
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance	Feb. 15	GL
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance	Feb. 15	AQ
Valneva Announces Sale of Priority Review Voucher for $103 Million	Feb. 05	GL
Valneva Announces Sale of Priority Review Voucher for $103 Million	Feb. 05	AQ
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine	Jan. 10	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Valneva

Equities

VLA

FR0004056851

Press Releases

Filters